Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of APL-130277 in Parkinson's disease with OFF episodes
2016-000636-18Phase 3Terminated
- Sponsor
- Sunovion
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing APL-130277 with Placebo (2 arms). Primary endpoint: Mean change from pre-dose in MDS-UPDRS Part III Motor Examination score at 30 minutes after dosing at Week 12. Started Mar 2016; status: terminated.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-000636-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000636-18.